Background
==========

Despite recent advances in prevention and management of heart disease, death due to post-myocardial infarction (MI) heart failure (HF) continues to rise and new treatments are needed \[[@B1]\]. β~1~- and β~2~--adrenergic receptors (ARs) are the main stimulatory receptors of cardiac function but are now known to play clearly distinct roles in cardiac physiology and pathology \[[@B2]-[@B5]\]. For instance, cardiomyocyte contraction is readily stimulated by β~1~ARs but not β~2~ARs and β~1~AR signaling is generally considered pro-apoptotic whereas β~2~AR signaling anti-apoptotic in the heart \[[@B2]-[@B5]\]. These differences might be explained by differences in the signaling complexes assembled by activation of these two βARs: β~1~AR forms a complex with phosphodiesterase (PDE) 4D8 directly when inactive, and agonist binding dissociates it \[[@B6],[@B7]\]. Additionally, β~1~AR does not readily bind the receptor adapter proteins beta-arrestins (βarrs) following its agonist-promoted phosphorylation by G protein coupled receptor kinases (GRKs), the most prominent members of which in the heart are GRK2 and −5 \[[@B8]-[@B11]\]. In contrast, β~2~AR recruits another PDE variant upon its agonist activation, PDE4D5, via its interaction with βarrs following its GRK-dependent phosphorylation \[[@B6],[@B7],[@B12]-[@B16]\]. PDE recruitment to the receptor's signaling complex plays a crucial role in compartmentalizing the cyclic adenosine monophosphate (cAMP) signal and thereby tightly regulating βAR-stimulated contractility \[[@B7]\]. It has been postulated that this PDE4D5 recruitment to the agonist-activated cardiac β~2~AR poses a "brake" on the β~2~AR cAMP signaling's ability to stimulate contractility \[[@B6],[@B7],[@B13],[@B15]\]. By contrast, agonist-promoted dissociation of PDE from the β~1~AR underlies the more "diffuse" and more powerful at stimulating contraction signaling of this βAR subtype \[[@B6],[@B7]\]. Of note, cardiac β~2~AR signaling has been reported to become more "diffuse" and decompartmentalized, i.e. to adopt a β~1~AR-like signaling pattern, in a rat model of HF, which might underlie cardiac β~2~AR dysfunction in HF \[[@B17]\].

On the other hand, cardiac β~2~AR can switch its signaling from G~s~ protein-mediated to G~i/o~ protein-mediated, which is believed to underlie its anti-apoptotic effects and is a feature cardiac β~1~ARs lack \[[@B18]-[@B24]\]. Finally, the interactions of the β~2~AR with the βarrs, which require prior receptor phosphorylation by GRKs, can have pleiotropic effects in cardiac myocytes, such as inhibition of apoptosis/promotion of survival by promoting extracellular signal-regulated kinase (ERK) signaling \[[@B25]\] and inhibition of inflammation by blocking the pro-inflammatory transcription factor nuclear factor-kappaB (NF-κB) \[[@B26],[@B27]\], a crucial mediator of major pro-inflammatory cytokine expression, such as tumor necrosis factor-alpha (TNF-α) and interleukin-1 and −6 (IL-1 & -6) \[[@B28]-[@B30]\]. These βarr-dependent signaling effects may also play some part in the well known and described anti-apoptotic and other beneficial in post-MI HF effects of cardiac β~2~AR.

Cardiac GRK2 is a major negative regulator of βAR pro-contractile signaling \[[@B8]-[@B11]\]. By desensitizing both β~1~- and β~2~ARs, i.e. terminating their G protein-mediated signaling through cAMP, it dramatically reduces cardiac inotropic and adrenergic reserves, and since it is markedly elevated in HF, its blockade represents an attractive therapeutic strategy for heart disease treatment \[[@B8]-[@B11],[@B31]-[@B35]\]. Given that GRK2 can block the pro-contractile and other beneficial signaling of cardiac β~2~AR in HF, and also that its action on β~2~AR induces recruitment of βarrs with all their aforementioned myriad effects on this receptor's signaling, we hypothesized, in the present study, that cardiac GRK2 blockade in vivo might enhance β~2~AR signaling post-MI. In order to study the effects of GRK2 blockade specifically on this subtype's signaling, without any interference by the qualitatively different β~1~AR signaling, we utilized the β~1~AR knockout (B1KO) mice \[[@B36]\], which we crossed with mice overexpressing the known GRK2 inhibitor mini-gene βARKct (or GRK2ct) specifically in cardiac myocytes \[[@B32]\]. After breeding the offspring to homozygosity, we studied them both under normal conditions (i.e. healthy, sham-operated animals) and after surgically induced MI to induce HF. We found that GRK2 inhibition in vivo is absolutely necessary for the β~2~AR to be capable of increasing contractility. In addition, β~2~AR anti-apoptotic signaling post-MI is augmented by βARKct, but only acutely.

Results
=======

βARKct restores cardiac β~2~AR-dependent pro-contractile signaling by reducing the interaction of PDE4D with the receptor
-------------------------------------------------------------------------------------------------------------------------

We developed the hybrid transgenic line βARKct/B1KO by crossing the B1KO mice with the βARKct transgenic mice, which express βARKct only in cardiomyocytes. The βARKct/B1KO's breed normally, without any gross abnormalities and present no overt cardiovascular or other phenotype (data not shown). Three-month-old male mice were chosen to undergo surgical MI in order to induce HF and were studied alongside age-matched male homozygous B1KO's (without βARKct expression), which served as the control group.

Since GRK2 is a major (negative) regulator of cardiac βAR-dependent contractility in vivo, and the β~2~AR stimulates contractility only very weakly, we first examined the cardiac function parameters of these mice, both in sham and post-MI groups. Echocardiography revealed that the B1KO mice display significantly decreased ejection fraction compared to control wild type (WT) mice, both under normal conditions (sham groups) and at 4 weeks post-MI, as expected since the β~1~AR is the major βAR subtype in the heart stimulating contractility (Table [1](#T1){ref-type="table"}) \[[@B8]\]. Notably, βARKct overexpression led to significant augmentation of the ejection fraction of the B1KO mice, up to the levels of WT mice, again both in normal and in 4 week post-MI mice (Table [1](#T1){ref-type="table"}), while, as already known from our studies in the past \[[@B10],[@B11],[@B32],[@B33]\], βARKct significantly augments contractility of the WT mice, as well (Table [1](#T1){ref-type="table"}). Importantly, when the mice underwent in vivo cardiac catheterization to measure their hemodynamic responses to isoproterenol stimulation (a standard βAR full agonist), B1KO mice, remarkably, completely failed to show any increase in contractility (as measured by the +dP/dt~max~ LV pressure elevation parameter), even at the highest concentration of isoproterenol challenge (Max. Iso, Table [1](#T1){ref-type="table"}). In contrast, the hybrid βARKct/B1KO mice showed very good contractile responses to isoproterenol, both in the sham (healthy) conditions and in post-MI HF (Table [1](#T1){ref-type="table"}). As expected, the other two mouse lines, i.e. WT and βARKct, were responsive to βAR stimulation, with the HF animals in these groups showing somewhat reduced responses compared to their sham counterparts and the βARKct line displaying much more robust responses compared to the WT group (Table [1](#T1){ref-type="table"}). These results strongly indicate that cardiac GRK2 is a major opposing force for the β~2~AR pro-contractile function and only when its activity is blocked (e.g. in the presence of βARKct) is the cardiac β~2~AR capable of promoting contractility in response to agonist stimulation.

###### 

In vivo cardiac functional parameters

                  **Parameter**                   **WT-Sham**   **βARKct-Sham**   **B1KO-Sham**   **βARKct/ B1KO-Sham**   **WT-MI**   **βARKct-MI**   **B1KO-MI**    **βARKct/ B1KO-MI**
  ---------------------------------------------- ------------- ----------------- --------------- ----------------------- ----------- --------------- -------------- ---------------------
        **Infarct size (% LV free wall)**             N/A             N/A              N/A                 N/A             41±1.2        42±2.2          40±2.6            43±3.0
                    **FS (%)**                     41.4±1.3       48.3±2.8\^       36.7±2.6\^         41.3±2.4^\#^        18.6±2.2     23.7±1.3^+^    11.0±1.4^+^        19.0±2.4\*
                    **EF (%)**                     72.0±1.0       78.0±2.0\^       67.0±2.4\^         72.0±2.0^\#^        37.5±3.0     45.3±2.4^+^    23.7±2.5^+^        38.5±4.2\*
              **Basal HR (min--1)**                 385±12          402±37           402±27              383±23            392±12        408±10          391±8             389±13
    **Basal LV +dP/dt**~**max**~**(mm Hg/s)**      4692±363       6835±637\^       3572±287\^         4576±375^\#^        3512±220     4900±172^+^    2576±155^+^        3549±231\*
    **Basal LV --dP/dt**~**min**~**(mm Hg/s)**     −4568±452      −6714±536\^      −3269±296\^        −4782±286^\#^       −3515±246   −4620±203^+^    −2592±233^+^       −3471±194\*
             **Max. Iso-HR (min--1)**               557±36          515±40          405±28\^            393±14\^           509±24       581±17^+^      399±11^+^          413±20^+^
   **Max. Iso-LV +dP/dt**~**max**~**(mm Hg/s)**    8825±644       13547±476\^      3611±286\^         9041±528^\#^        5641±431     9419±601^+^    2639±139^+^        5628±419\*
   **Max. Iso-LV--dP/dt**~**min**~**(mm Hg/s)**    −7210±430      −8837±491\^      −3199±279\^        −6344±364^\#^       −5880±303   −6948±277^+^    −2605±251^+^       −5548±382\*

Cardiac parameter values of three-month-old wild type (WT, i.e. C57/B6), βARKct, B1KO and βARKct/B1KO mice measured at 4 weeks after MI or sham operation (Sham). *LV +dP/dt*~*max*~ maximal first derivative of LV pressure rise, *LV --dP/dt*~*min*~ minimal first derivative of LV pressure fall, *HR* heart rate, FS, fractional shortening, *EF* ejection fraction, *LV* Left ventricular, *N/A* Not applicable, Max. Iso dose: 333 ng/kg body weight. ^\#^, p\<0.05, vs. B1KO-Sham; \*, p\<0.05, vs. B1KO-MI; \^, p\<0.05, vs. WT-Sham; ^+^, p\<0.05, vs. WT-MI; n=7 mice/group. One-way ANOVA with Bonferroni test was performed among groups. Data are presented as mean ± SEM.

To identify the main signaling mechanism underlying this dramatic effect of βARKct on cardiac β~2~AR-dependent contractiity, we examined the levels of PDE4D interaction with the β~2~AR in cardiac membranes of these mice in vivo. As shown in Figures [1](#F1){ref-type="fig"}A and [1](#F1){ref-type="fig"}B, the interaction of cardiac β~2~AR with both the PDE4D3 and -D5 isoforms is significantly reduced in βARKct/B1KO mouse hearts compared to control B1KO hearts, an effect that might enable βARKct to enhance cardiac β~2~AR-dependent pro-contractile signaling in vivo.

![**β2AR-PDE4D interaction in the heart.** Co-immunoprecipitation (co-IP) followed by western blotting in cardiac extracts from normal (sham) B1KO and βARKct/B1KO (CT/B1KO) mice to measure the β~2~AR-PDE4D interaction in the heart. Representative immunoblots are shown in **(A)**, and the amounts of the co-immunoprecipitated PDE4D isoforms, as measured by densitometry and normalized with the amount of β~2~AR pulled down in the co-IP, are shown in **(B)**. \*, p\<0.05, vs. B1KO; n=4 independent experiments (i.e. performed on 4 different hearts from each mouse line). IP: Immunoprecipitation, IB: Immunoblotting.](1478-811X-11-64-1){#F1}

βARKct and cardiac β~2~AR-dependent anti-apoptotic/inflammatory signaling
-------------------------------------------------------------------------

Next, we examined the impact of βARKct expression on the other major aspect of cardiac β~2~AR signaling, anti-apoptosis/cardiac survival. Post-MI βARKct/B1KO mice display markedly better survival post-MI compared to their B1KO counterparts (Figure [2](#F2){ref-type="fig"}A). Kaplan-Meier survival curves indicated that at 4 weeks post-MI, a significant (\~70%) of βARKct/B1KO's are still alive, compared to only \~40% of B1KO's at the same time point post-MI (Figure [2](#F2){ref-type="fig"}A). In addition, cardiac apoptosis is found significantly decreased very early (at 24 hrs) post-MI in the βARKct/B1KO hearts compared to control B1KO hearts (Figure [2](#F2){ref-type="fig"}B) but similar between the two groups at 4 weeks post-MI (Figure [2](#F2){ref-type="fig"}B), indicating that this reduction in post-MI apoptosis induced by βARKct is short-lived. As for post-MI cardiac inflammation in the two animal groups, levels of the major pro-inflammatory cytokines TNFα(Figure [2](#F2){ref-type="fig"}C), IL-6 (Figure [2](#F2){ref-type="fig"}D) and IL-1β (Figure [2](#F2){ref-type="fig"}E) are significantly increased in the hearts of βARKct/B1KO mice, compared to control B1KO hearts at 24 hrs post-MI, indicating increased wound (infarct) healing-associated inflammation. By 4 weeks post-MI however, levels of all these three cytokines (TNFα, IL-6, IL-1β) in βARKct/B1KO hearts have returned to the levels of 24-hour post-MI B1KO hearts (data not shown), indicating that also the effect of βARKct on post-MI inflammation is short-lived.

![**Survival, cardiac apoptosis and inflammation post-MI. (A)** Kaplan-Meier survival curves of the 4 groups of mice of the study: sham-operated (Sham) and post-MI (MI) B1KO and βARKct/B1KO mice. p=0.011 between MI B1KO and MI βARKct/B1KO; n=15 mice/group for sham, 37 mice/group for MI mice. **(B)** Apoptotic cell death at 24 hrs and at 4 weeks (wks) post-MI in the two transgenic (B1KO and CT/B1KO) lines, as measured by TUNEL performed in the border zone of the infarct. No difference in rate of apoptosis in the remote zone at either post-MI time point was found (data not shown). \*\*, p\<0.05, vs. B1KO 24 hrs, n=6 mice/group. **(C-E)** Levels of pro-inflammatory cytokines TNFα **(C)**, IL-6 **(D)**, and IL-1β **(E)**, measured via ELISA in serum of intra-cardiac blood from B1KO and βARKct/B1KO (CT/B1KO) mice at 24 hrs post-MI. \*, p\<0.05, n=5 mice/group.](1478-811X-11-64-2){#F2}

To identify potential signaling mechanisms underlying these effects of βARKct on apoptosis and inflammation in post-MI B1KO hearts, we examined protein levels of the major anti-apoptotic mediator Bcl-2 \[[@B37]\] and levels of activation of the crucial pro-inflammatory transcription factor NFκB. Bcl-2 was found significantly up-regulated in βARKct/B1KO hearts compared to control B1KO hearts at 24 hrs post-MI (Figures [3](#F3){ref-type="fig"}A and [3](#F3){ref-type="fig"}B), indicating enhanced cellular survival/inhibition of apoptosis. However, at 4 weeks post-MI, Bcl-2 protein was virtually undetectable in the hearts of both mouse lines (Figure [3](#F3){ref-type="fig"}C), which is consistent with the phenotypic finding of the short-lived inhibition of apoptosis in the heart by βARKct (Figure [2](#F2){ref-type="fig"}B). In addition, NFκB activation appears also markedly elevated in βARKct/B1KO hearts compared to control B1KO hearts at 24 hrs post-MI (Figures [3](#F3){ref-type="fig"}A and [3](#F3){ref-type="fig"}B), indicating enhanced cardiac inflammation. For NFκB to get activated, its inhibitory IκBα subunit must be phosphorylated and subsequently targeted for proteasomal degradation to release the transcriptionally active subunits of the complex \[[@B28]-[@B30]\]. Thus, increased phosphorylation of IκBα and decreased levels (increased degradation) of total IκBα in the hybrid transgenic hearts at 24 hrs post-MI (Figures [3](#F3){ref-type="fig"}A and [3](#F3){ref-type="fig"}B) suggest increased NFκB activation compared to B1KO hearts. Finally, blotting for βARKct in these hearts confirmed the robust expression of this GRK2 inhibitor in the hearts of βARKct/B1KO's, which, of course, was absent from the hearts of B1KO mice (Figure [3](#F3){ref-type="fig"}A).

![**Levels of cardiac Bcl-2, NFκB activity and GRK5 post-MI. (A-B)** Western blotting in total cardiac extracts from 24 hr post-MI B1KO and βARKct/B1KO (CT/B1KO) mice for βARKct, Bcl-2, phospho-IκBα (pIκBα), and total IκBα. Representative blots are shown in **(A)**, including blots for glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as loading control for each protein tested, and densitometric quantitation, normalized with GAPDH as control and expressed as % of B1KO levels, of 4 independent experiments done in duplicate, is shown in **(B)**. \*, p\<0.05, vs. B1KO. **(C)** Western blotting for Bcl-2 protein in total cardiac extracts from 4 week post-MI B1KO and βARKct/B1KO (CT/B1KO) mice. Representative blots from 4 independent experiments done in duplicate are shown, including GAPDH as loading control and h9c2 cell extract as positive control (input) for Bcl-2. Bcl-2 was virtually undetectable in either group at 4 weeks post-MI. **(D)** Western blotting for GRK5 in total cardiac extracts from B1KO and βARKct/B1KO (CT/KO) mice at 24 hrs and at 4 weeks (wks) post-MI. Representative blots of 4 independent experiments done in duplicate, with GAPDH as loading control, are shown on top, and densitometric quantitation on bottom. \*, p\<0.05, vs. all other groups.](1478-811X-11-64-3){#F3}

GRK5 and cardiac β~2~AR-dependent signaling
-------------------------------------------

Apart from GRK2, the other major cardiac GRK that can phosphorylate and desensitize β~2~ARs, and thus oppose β~2~AR pro-contractile and anti-apoptotic signaling, is GRK5 \[[@B8]-[@B10]\]. As shown in Figure [3](#F3){ref-type="fig"}D, cardiac post-MI GRK5 levels are initially (at 24 hrs post-MI) similar between the two groups, as is the case also in the healthy, sham-operated groups (data not shown). By 4 weeks post-MI however, a significant up-regulation (\~2-fold increase) of GRK5 is observed in βARKct/B1KO hearts compared to control B1KO hearts (Figure [3](#F3){ref-type="fig"}D), indicating that GRK2 inhibition with βARKct leads to a compensatory up-regulation of GRK5 over time.

Discussion
==========

The present study reports for the first time, to our knowledge, that cardiac GRK2 is an endogenous "stumbling block" that normally prevents β~2~AR signaling from stimulating contractility, mainly because it promotes association of this βAR subtype with PDE4D in the heart, a major molecular "brake" on cardiac β~2~AR-dependent contractility \[[@B6],[@B7],[@B15]\]. Thus, only when cardiac GRK2 is blocked (e.g. with βARKct) is the β~2~AR capable of promoting cardiac contractility. Obviously, several signaling mechanisms/pathways are at play, the present study has identified the following two: 1) βARKct, by blocking GRK2, reduces the uncoupling of β~2~AR with the classical pro-contractile G~s~ protein-adenylyl cyclase-cAMP-PKA signaling pathway (Figure [4](#F4){ref-type="fig"}), and 2) GRK2 blockade reduces the interaction of β~2~AR with βarrs, which scaffold on themselves various isoforms of PDE4D (mainly PDE4D3 and PDE4D5) (Figure [4](#F4){ref-type="fig"}). PDE4D causes degradation of the local cAMP signals produced by activated β~2~AR, which are essential for stimulation of contractility, and thus it weakens these pro-contractile signals hampering β~2~AR-stimulated contractility \[[@B6],[@B7],[@B15]\]. By indirectly reducing the βarr-PDE4D interaction with the cardiac β~2~AR, βARKct releases the "brake" PDE4D poses on this receptor's pro-contractile signaling and enhances its capacity to stimulate contractility (Figure [4](#F4){ref-type="fig"}).

![**Schematic illustration of the signaling pathways discussed in the present study that are elicited by β**~**2**~**AR activation in cardiac myocytes and are affected by GRK2 inhibition with βARKct.** CA: Catecholamine; AC: Adenylyl cyclase; ATP: adenosine triphosphate. See text for details and all other molecular acronym descriptions.](1478-811X-11-64-4){#F4}

Since the other major beneficial effect of cardiac β~2~AR signaling in vivo is inhibition of apoptosis (promotion of survival), we also tested the effects of cardiac GRK2 blockade in vivo on this aspect of β~2~AR signaling in the context of post-MI HF progression. We found that early on after MI, cardiac GRK2 blockade with βARKct also dramatically augments β~2~AR anti-apoptotic signaling, as well as its pro-infarct healing inflammatory signaling, in the heart. This results in significant reduction in all-cause mortality (marked increase in animal survival in the first 4 weeks post-MI), and reduced cellular apoptosis in the post-MI heart, compared to B1KO mice with unopposed cardiac GRK2 activity. Thus, βARKct enhances not only cardiac contractility, but also cardiac survival stimulated by the β~2~AR, which further reinforces its validity as an attractive therapeutic strategy to potentiate cardiac β~2~AR signaling and function in post-MI HF. Of course, enhancement of the anti-apoptotic signaling of other cardio-protective receptors that are also GRK2 substrates by βARKct cannot be ruled out and is, in fact, quite likely to have contributed to the observed cardiac apoptosis phenotype of βARKct/B1KO mice. However, βARKct's cardio-protective and anti-apoptotic effects have been shown to be β~2~AR-dependent, since selective blockade of this receptor in cardiac myocytes abolishes βARKct-mediated anti-apoptotic effects \[[@B38]\]. On the other hand, effects of βARKct on β~2~AR-dependent pro-angiogenetic signaling, which plays an important role in peri-infarct HF progression \[[@B39]\], cannot be ruled out either. Nevertheless, it becomes quite clear from our current data that βARKct augments β~2~AR contractile function without negatively affecting its anti-apoptotic one, but rather actually preserving and further enhancing this β~2~AR function, as well.

However, this augmentation of anti-apoptotic signaling is short-lived: by 4 weeks post-MI, cardiac cellular apoptosis has returned to the 24-hour post-MI B1KO heart levels. This might be related to the nature of cardiac β~2~AR pro-survival signaling; β~2~AR can have remarkably different effects in the heart depending on its expression levels and on time \[[@B40],[@B41]\]. Cardiac β~2~AR is known to be beneficial (i.e. promoting survival) at low levels of overexpression and in the first few months of life in mice, but when overexpressed at extremely high levels in murine hearts or later on in the mouse's life, these animals do not survive and die of severe cardiac complications \[[@B40]\]. Mechanistically, cardiac β~2~AR anti-apoptotic signaling is known to proceed mainly through the G~i/o~ protein signaling pathway \[[@B20]-[@B23]\], to which it is capable of switching following its phosphorylation by PKA \[[@B42]\]. GRK2 blockade by βARKct can increase this signaling by a) decreasing the pathway's βarr-mediated desensitization, i.e. increasing the coupling of G~i/o~ proteins with the β~2~AR, and b) by increasing the PKA-dependent switching of β~2~AR signaling from G~s~ to G~i/o~ proteins thanks to the increase of β~2~AR signaling via the G~s~ protein-cAMP-PKA (the pro-contractile) pathway it also causes, discussed above (Figure [4](#F4){ref-type="fig"}). With regards to the pro-inflammatory signaling of cardiac β~2~AR, βarrs are known to scaffold and stabilize the inhibitory IκBα subunit of NFκB, thereby prohibiting NFκB activation \[[@B26],[@B27]\]. GRK2 blockade with βARKct decreases βarr interaction with the β~2~AR thereby "releasing" the inhibitory effect of βarrs on NFκB activation (Figure [4](#F4){ref-type="fig"}). Thus, NFκB activation and the subsequent pro-inflammatory cytokine production are enhanced (Figure [4](#F4){ref-type="fig"}). Indeed, NFκB activation and inflammatory cytokine levels were found significantly elevated in βARKct/B1KO hearts compared to B1KO hearts without GRK2 inhibition at 24 hrs post-MI.

Meanwhile however, βARKct also causes upregulation of the other major cardiac GRK, GRK5, in the first few weeks post-MI. This is also probably due to the enhanced NFκB activation (Figure [4](#F4){ref-type="fig"}), since NFκB can cause upregulation of GRK5 in cardiomyocytes \[[@B43]\]. Importantly, and given that GRK5 elevation is generally considered detrimental for the heart \[[@B8]-[@B10]\], this finding might explain, at least in part, the aforementioned switching of cardiac β~2~AR signaling from beneficial (anti-apoptotic) early in life of transgenic mice or at low levels of receptor expression to detrimental (pro-apoptotic) later on in the lifespan of these mice or at very high levels of cardiac β~2~AR overexpression \[[@B41]\]. Of note, GRK5 has also been reported to bind (via its non-catalytic, N-terminal domain) to, and stabilize IκBα, thereby inhibiting NFκB activity in several tissues, including the heart \[[@B44]\]. Therefore, our present findings strongly indicate that a negative feedback loop might exist in the heart, in which NFκB induces GRK5 expression, and GRK5 can subsequently suppress NFκB activation (Figure [4](#F4){ref-type="fig"}).

Conclusions
===========

In summary, the present study reports that cardiac GRK2 inhibition with βARKct in vivo is absolutely essential for the cardiac β~2~AR subtype's pro-contractile function, all the while preserving and augmenting this receptor's beneficial anti-apoptotic/pro-survival and pro-infarct healing signaling pathways post-MI, early on after the cardiac insult. However, the effects of βARKct on the latter signaling modalities are transient due (in part) to compensatory elevation of cardiac GRK5 over time.

Methods
=======

Experimental animals and surgical procedures
--------------------------------------------

The animals in this study were handled according to animal welfare regulations and protocols approved by the authors' Institutional Review Boards. Genetically engineered, 8- to 12-wk-old β~1~AR KO (B1KO) (on C57/B6 background) \[[@B36]\] and the offspring of their cross with Mini-27 mice, expressing the βARKct (or GRK2ct) transgene under the alpha-myosin heavy chain gene promoter \[[@B32]\], were used for this study. Mice were anesthetized with a mixture of ketamine (100 mg/kg) and xylazine (2.5 mg/kg). Animals were placed in the supine position on a heated operation board and a midline cervical incision was made to expose the trachea. Following successful endotracheal intubation, the cannula was connected to a rodent ventilator. The entire left ventricle (i.e. both infarct and non-infarct zones) were used for subsequent histological and biochemical assays. Myocardial infarction was performed as previously described \[[@B35]\].

Echocardiography & in vivo hemodynamics
---------------------------------------

Transthoracic echocardiography was performed with a linear 30-MHz transducer (VeVo 770 High Resolution Imaging System, VisualSonics, Toronto, ON, Canada), as described \[[@B35]\]. In vivo hemodynamic analysis was also performed as previously described \[[@B35]\].

In situ TUNEL staining
----------------------

Heart specimens were fixed with 10% neutral buffered formalin, embedded in paraffin, and sectioned at 5-μm thickness. DNA fragmentation was detected in situ in deparaffinized sections using the ApopTag Kit (Intergene) and according to manufacturer's instructions, as described previously \[[@B45]\]. The total number of nuclei was determined by manual counting of DAPI-stained nuclei in six random fields per section. All terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL)-positive nuclei were counted in each section.

Co-immunoprecipitation and western blotting
-------------------------------------------

Cardiac extracts were prepared in 20 mM Tris pH 7.4, 137 mM NaCl, 1% Nonidet P-40, 20% glycerol, 10 mM PMSF, 1 mM Na~3~VO~4~, 10 mM NaF, 2.5 μg/ml aprotinin, and 2.5 μg/ml leupeptin. Protein concentration was then determined and equal amounts of protein per sample were loaded on SDS-PAGE gels for electrophoretic separation, as described previously \[[@B46]\]. For β~2~AR-PDE4D co-immunoprecipitation experiments, β~2~AR was immunoprecipitated with an anti-mouse β~2~AR antibody (sc-9042, Santa Cruz), immobilized on Protein A-sepharose beads (Invitrogen), prior to SDS-PAGE/western blotting. Total IκBα and phospho-IκBα were detected by using anti-IκBα (sc-1643, Santa Cruz) and anti-phosphoIκBα at Ser-32 (sc-7977, Santa Cruz) antibodies, Bcl-2, GRK5, GRK2/βARKct and GAPDH, with antibodies sc-492, sc-565, sc-562, and sc-25778, respectively (all from Santa Cruz), and PDE4D (various isoforms) with the PD4-401AP antibody (FabGennix). Immunoblots were revealed by enhanced chemiluminescence (ECL, Amersham Biosciences) and visualized in the FluorChem E Digital Darkroom (Cell Biosciences). Densitometry was performed with the AlphaView software (Cell Biosciences) in the linear range of signal detection (on non-saturated bands).

Cytokine measurements via ELISA
-------------------------------

Pro-inflammatory cytokines TNFα, IL-6 and IL-1β were measured in serum obtained from left ventricular blood, immediately prior to heart excision and animal euthanizing, via multiplexed ELISA, as described \[[@B47],[@B48]\]. The assay was performed using the Mouse Cytokine ELISA Profiling Kit (EA-1091, Signosis), according to the manufacturer's instructions.

Statistical analyses
--------------------

Data are generally expressed as mean ± SEM. Unpaired 2-tailed Student's *t* test and one- or two-way ANOVA with Bonferroni test were generally performed for statistical comparisons, unless otherwise indicated. For all tests, a p value of \<0.05 was generally considered to be significant.

Abbreviations
=============

βAR: Beta-adrenergic receptor; B1KO: β~1~AR knockout; GRK: G protein-coupled receptor kinase; βARKct: Beta-adrenergic receptor kinase (GRK2) carboxyl terminal fragment; βarr: Beta-arrestin; PDE: Phosphodiesterase; MI: Myocardial infarction; HF: Heart failure; NFκB: Nuclear factor-kappaB; IκBα: Inhibitor of nuclear factor-kappaB alpha subunit; cAMP: 3′-5′ adenosine monophosphate (cyclic adenosine monophosphate); WT: Wild type; PKA: Protein kinase A; Gs: Stimulatory G protein; Gi/o: Inhibitory or other G protein; TNFα: Tumor necrosis factor alpha; IL: Interleukin; TUNEL: Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling; Bcl-2: B-cell lymphoma 2; LV: Left ventricular; ELISA: Enzyme-linked immunosorbent assay.
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